₹533.5
▼ -0.1 -0.02%
17 Jun 2026
NSE Listed · Healthcare
Thyrocare Tech Ltd. (THYROCARE)
20-day avg volume: 2.7L shares
- Healthy return on equity of 27.9%.
- Pays a dividend yield of 2.6%.
- Company is almost debt-free.
- Revenue grew 20% YoY.
- Net profit is growing year over year.
| Metric | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sept 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sept 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sept 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sept 2020 | Jun 2020 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹224 Cr | ₹196 Cr | ₹217 Cr | ₹193 Cr | ₹187 Cr | ₹166 Cr | ₹177 Cr | ₹157 Cr | ₹154 Cr | ₹135 Cr | ₹148 Cr | ₹135 Cr | ₹136 Cr | ₹128 Cr | ₹135 Cr | ₹128 Cr | ₹131 Cr | ₹117 Cr | ₹176 Cr | ₹165 Cr | ₹147 Cr | ₹138 Cr | ₹153 Cr | ₹56 Cr | ₹101 Cr |
| EBITDA | ₹65 Cr | ₹41 Cr | ₹63 Cr | ₹51 Cr | ₹49 Cr | ₹29 Cr | ₹38 Cr | ₹35 Cr | ₹24 Cr | ₹21 Cr | ₹29 Cr | ₹26 Cr | ₹18 Cr | ₹20 Cr | ₹24 Cr | ₹28 Cr | ₹30 Cr | ₹29 Cr | ₹96 Cr | ₹74 Cr | ₹47 Cr | ₹44 Cr | ₹59 Cr | ₹3 Cr | ₹25 Cr |
| Net Profit | ₹47 Cr | ₹29 Cr | ₹48 Cr | ₹39 Cr | ₹22 Cr | ₹19 Cr | ₹27 Cr | ₹24 Cr | ₹18 Cr | ₹15 Cr | ₹20 Cr | ₹17 Cr | ₹13 Cr | ₹15 Cr | ₹15 Cr | ₹22 Cr | ₹21 Cr | ₹22 Cr | ₹78 Cr | ₹56 Cr | ₹38 Cr | ₹32 Cr | ₹43 Cr | ₹0 Cr | ₹-2 Cr |
| EPS | 2.98 | 1.81 | 9.03 | 7.33 | 4.17 | 3.56 | 4.99 | 4.51 | 3.54 | 2.77 | 3.84 | 3.25 | 2.36 | 2.77 | 3.8 | 4.1 | 4.03 | 4.05 | 14.67 | 10.48 | 7.13 | 6.12 | 8.13 | 0.04 | -0.3 |
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹846 Cr | ₹702 Cr | ₹581 Cr | ₹535 Cr | ₹618 Cr | ₹507 Cr | ₹441 Cr |
| EBITDA | ₹220 Cr | ₹150 Cr | ₹100 Cr | ₹90 Cr | ₹230 Cr | ₹153 Cr | ₹148 Cr |
| Net Profit | ₹163 Cr | ₹92 Cr | ₹71 Cr | ₹64 Cr | ₹176 Cr | ₹113 Cr | ₹88 Cr |
| EPS | 10.24 | 5.69 | 13.4 | 12.14 | 33.25 | 21.37 | 16.71 |
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹747 Cr | ₹693 Cr | ₹644 Cr | ₹633 Cr | ₹608 Cr | ₹546 Cr | ₹471 Cr |
| Total Liabilities | ₹161 Cr | ₹146 Cr | ₹116 Cr | ₹98 Cr | ₹81 Cr | ₹119 Cr | ₹104 Cr |
| Equity | ₹586 Cr | ₹547 Cr | ₹528 Cr | ₹535 Cr | ₹527 Cr | ₹427 Cr | ₹367 Cr |
| Total Debt | ₹0 Cr | ₹0 Cr | ₹11 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr |
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Operating | ₹273 Cr | ₹231 Cr | ₹197 Cr | ₹158 Cr | ₹170 Cr | ₹158 Cr | ₹212 Cr |
| Investing | ₹-23 Cr | ₹-41 Cr | ₹-91 Cr | ₹-39 Cr | ₹-24 Cr | ₹-49 Cr | ₹1 Cr |
| Financing | ₹-170 Cr | ₹-130 Cr | ₹-85 Cr | ₹-86 Cr | ₹-89 Cr | ₹-62 Cr | ₹-165 Cr |
| Free Cash Flow | ₹273 Cr | ₹231 Cr | ₹197 Cr | ₹158 Cr | ₹170 Cr | ₹158 Cr | ₹212 Cr |
Healthcare · Healthcare
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of testing equipment and consumables; and glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search